Healthcare provider profile · identity verified

Matthew J Riffle, M.D.

Internal Medicine · POPLAR BLUFF, MO · NPI 1770537367

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	387	74
Levothyroxine Sodium	Levothyroxine Sodium	333	45
Gabapentin	Gabapentin	250	54
Eliquis	Apixaban	238	33
Amlodipine Besylate	Amlodipine Besylate	230	51
Losartan Potassium	Losartan Potassium	212	39
Pantoprazole Sodium	Pantoprazole Sodium	210	45
Omeprazole	Omeprazole	205	53
Metoprolol Tartrate	Metoprolol Tartrate	204	50
Tamsulosin Hcl	Tamsulosin Hcl	195	36
Furosemide	Furosemide	186	41
Potassium Chloride	Potassium Chloride	166	36
Metoprolol Succinate	Metoprolol Succinate	144	33
Simvastatin	Simvastatin	141	36
Alprazolam	Alprazolam	139	38
Lisinopril	Lisinopril	111	28
Mirtazapine	Mirtazapine	109	14
Sertraline Hcl	Sertraline Hcl	103	16
Fluoxetine Hcl	Fluoxetine Hcl	102	21
Clopidogrel	Clopidogrel Bisulfate	99	14
Carvedilol	Carvedilol	94	16
Famotidine	Famotidine	88	20
Escitalopram Oxalate	Escitalopram Oxalate	85	14
Montelukast Sodium	Montelukast Sodium	83	18
Duloxetine Hcl	Duloxetine Hcl	77	13
Rosuvastatin Calcium	Rosuvastatin Calcium	74	15
Donepezil Hcl	Donepezil Hcl	73	11
Trazodone Hcl	Trazodone Hcl	69	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	66	16
Hydrochlorothiazide	Hydrochlorothiazide	61	17
Venlafaxine Hcl Er	Venlafaxine Hcl	61	suppressed
Ropinirole Hcl	Ropinirole Hcl	60	11
Prednisone	Prednisone	58	13
Allopurinol	Allopurinol	57	13
Oxcarbazepine	Oxcarbazepine	54	suppressed
Levetiracetam	Levetiracetam	53	suppressed
Metformin Hcl	Metformin Hcl	53	21
Quetiapine Fumarate	Quetiapine Fumarate	52	suppressed
Amiodarone Hcl	Amiodarone Hcl	50	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	49	28
Citalopram Hbr	Citalopram Hydrobromide	48	11
Buspirone Hcl	Buspirone Hcl	44	11
Memantine Hcl	Memantine Hcl	44	suppressed
Topiramate	Topiramate	44	suppressed
Dexlansoprazole Dr	Dexlansoprazole	40	suppressed
Jardiance	Empagliflozin	38	suppressed
Pravastatin Sodium	Pravastatin Sodium	38	11
Fluticasone Propionate	Fluticasone Propionate	37	18
Metformin Hcl Er	Metformin Hcl	37	11
Methocarbamol	Methocarbamol	37	suppressed
Tizanidine Hcl	Tizanidine Hcl	37	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	suppressed
Glimepiride	Glimepiride	35	11
Tramadol Hcl	Tramadol Hcl	34	17
Baclofen	Baclofen	33	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Digoxin	Digoxin	32	suppressed
Farxiga	Dapagliflozin Propanediol	32	suppressed
Tradjenta	Linagliptin	32	suppressed
Lamotrigine	Lamotrigine	31	suppressed
Warfarin Sodium	Warfarin Sodium	31	11
Zolpidem Tartrate	Zolpidem Tartrate	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Atenolol	Atenolol	28	suppressed
Entresto	Sacubitril/Valsartan	27	suppressed
Spironolactone	Spironolactone	26	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Xarelto	Rivaroxaban	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Vascepa	Icosapent Ethyl	22	suppressed
Finasteride	Finasteride	21	suppressed
Risperidone	Risperidone	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Olanzapine	Olanzapine	19	suppressed
Primidone	Primidone	19	suppressed
Terazosin Hcl	Terazosin Hcl	19	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Lorazepam	Lorazepam	18	12
Myrbetriq	Mirabegron	18	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Phenytek	Phenytoin Sodium Extended	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	15	suppressed
Anastrozole	Anastrozole	15	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	15	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Estradiol	Estradiol	15	suppressed
Humalog	Insulin Lispro	15	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Ozempic	Semaglutide	14	suppressed
Valsartan	Valsartan	14	suppressed
Bromocriptine Mesylate	Bromocriptine Mesylate	13	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Celecoxib	Celecoxib	12	suppressed
Glipizide	Glipizide	12	suppressed
Nabumetone	Nabumetone	12	suppressed
Naproxen	Naproxen	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Zonisamide	Zonisamide	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error